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ABSTRACT
Ross River virus (RRV) is one of a group of mosquito-transmitted alphaviruses that cause debilitating, and often chronic, mus-
culoskeletal disease in humans. Previously, we reported that replacement of the nonstructural protein 1 (nsP1) gene of the
mouse-virulent RRV strain T48 with that from the mouse-avirulent strain DC5692 generated a virus that was attenuated in a
mouse model of disease. Here we find that the six nsP1 nonsynonymous nucleotide differences between strains T48 and DC5692
are determinants of RRV virulence, and we identify two nonsynonymous nucleotide changes as sufficient for the attenuated phe-
notype. RRV T48 carrying the six nonsynonymous DC5692 nucleotide differences (RRV-T48-nsP16M) was attenuated in both
wild-type and Rag1/ mice. Despite the attenuated phenotype, RRV T48 and RRV-T48-nsP16M loads in tissues of wild-type and
Rag1/ mice were indistinguishable from 1 to 3 days postinoculation. RRV-T48-nsP16M loads in skeletal muscle tissue, but not
in other tissues, decreased dramatically by 5 days postinoculation in both wild-type and Rag1/ mice, suggesting that the RRV-
T48-nsP16M mutant is more sensitive to innate antiviral effectors than RRV T48 in a tissue-specific manner. In vitro, we found
that the attenuating mutations in nsP1 conferred enhanced sensitivity to type I interferon. In agreement with these findings,
RRV T48 and RRV-T48-nsP16M loads were similar in mice deficient in the type I interferon receptor. Our findings suggest that
the type I IFN response controls RRV infection in a tissue-specific manner and that specific amino acid changes in nsP1 are de-
terminants of RRV virulence by regulating the sensitivity of RRV to interferon.
IMPORTANCE
Arthritogenic alphaviruses, including Ross River virus (RRV), infect humans and cause debilitating pain and inflammation of
the musculoskeletal system. In this study, we identified coding changes in the RRV nsP1 gene that control the virulence of RRV
and its sensitivity to the antiviral type I interferon response, a major component of antiviral defense in mammals. Furthermore,
our studies revealed that the effects of these attenuating mutations are tissue specific. These findings suggest that these muta-
tions in nsP1 influence the sensitivity of RRV to type I interferon only in specific host tissues. The new knowledge gained from
these studies contributes to our understanding of host responses that control alphavirus infection and viral determinants that
counteract these responses.
Ross River virus (RRV) is a positive-sense, single-stranded RNAvirus in the Alphavirus genus of the family Togaviridae (1).
RRV is one of a group of related mosquito-transmitted alphavi-
ruses, including chikungunya virus (CHIKV), Mayaro virus,
o’nyong-nyong virus, and others, that typically cause a debilitat-
ing musculoskeletal inflammatory disease in humans. These vi-
ruses are emerging disease threats due to their ability to cause
explosive epidemics. Past epidemics include a 1979-to-1980 epi-
demic of RRV disease in the South Pacific that involved more than
60,000 patients (2) and a 1959-to-1962 epidemic of o’nyong-
nyong fever in Africa that involved at least 2 million infections (3).
Since 2004, CHIKV has caused major epidemics in multiple coun-
tries in the Indian Ocean region, with estimates on the order of 1
million to 6 million cases (4).
Clinical manifestations following infection with arthritis/my-
ositis-associated alphaviruses develop following an incubation pe-
riod ranging from 2 to 12 days (2, 5). The disease is most com-
monly characterized by fever, intense pain in the peripheral joints,
myalgias, and an impaired ability to ambulate (2, 6, 7). A number
of studies indicate that musculoskeletal pain lasts for months to
years in a subset of persons infected with RRV or CHIKV; how-
ever, the cause of these long-lasting symptoms is unclear (2, 8–12).
There are currently no licensed antivirals or vaccines for any of the
arthritis/myositis-associated alphaviruses. Treatment is limited to
supportive care with analgesics and anti-inflammatory drugs
(2, 5).
To study the pathogenesis of arthritis/myositis-associated al-
phaviruses, we have developed mouse models of RRV- and
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CHIKV-induced disease that recapitulate many aspects of the hu-
man diseases (13–17). Studies with the RRV mouse model dem-
onstrated that following a high-titer serum viremia, bone/joint-
associated tissues and skeletal muscle tissue are the primary targets
of RRV replication (15, 18). RRV replication at these sites results
in a severe inflammatory response with abundant tissue damage,
leading to deficits in grip strength and an altered gait. Human
disease following infection by an arthritogenic alphavirus shows a
similar progression, with (i) high-titer serum viremia (19, 20), (ii)
the detection of virus RNA and/or antigen in musculoskeletal tis-
sues (21, 22), (iii) mononuclear inflammatory infiltrates in joints
and muscle tissue (19, 22–24), and (iv) disease signs, such as mus-
culoskeletal pain and difficulty ambulating. Thus, understanding
the host and viral factors that contribute to pathogenesis in this
mouse model may aid in the development of therapies and vac-
cines to treat or prevent human disease.
Previously, we reported that replacement of the nonstructural
protein 1 (nsP1) coding region of RRV T48 with that from the
mouse-avirulent strain DC5692 resulted in an attenuated pheno-
type in the mouse model (25). Here we find that the six nsP1
nonsynonymous nucleotide differences between strains T48 and
DC5692 are determinants of RRV virulence, and we identify two
nonsynonymous nucleotide changes as sufficient for the attenu-
ated phenotype. RRV T48 encoding the six nonsynonymous
DC5692 nucleotides (RRV-T48-nsP16M) was attenuated in wild-
type (WT) and Rag1/ mice. RRV-T48-nsP16M loads in the tis-
sues of WT and Rag1/ mice were similar to those of the virulent
virus RRV T48 from 1 to 3 days postinoculation (dpi) but declined
sharply in skeletal muscle tissue, but not in joint tissue, by 5 dpi,
suggesting that the RRV-T48-nsP16M mutant is more sensitive to
innate antiviral effectors in a tissue-specific manner. In vitro, we
found that the attenuating mutations in nsP1 conferred enhanced
sensitivity to type I interferon (IFN). In agreement with these
findings, RRV T48 and RRV-T48-nsP16M loads in skeletal muscle
tissue and their virulence were similar in mice deficient in the type
I IFN receptor. Our findings suggest that specific amino acid
changes in nsP1 are determinants of RRV virulence by regulating
the sensitivity of RRV to IFN and that type I IFN controls RRV
infection in a tissue-specific manner.
MATERIALS AND METHODS
Viruses. The T48 strain of RRV (GenBank accession no. GQ433359) was
isolated from Aedes vigilax mosquitoes in Queensland, Australia. Prior to
cDNA cloning, the virus was passaged 10 times in suckling mice, followed
by 2 passages in Vero cells (26, 27). Thus, this strain may be adapted for
enhanced virulence in mice. RRV strain DC5692 (GenBank accession no.
HM234643) was isolated in 1995 from Aedes camptorhynchus mosquitoes
at Dawesville Cut in the Peel region of Western Australia (28). The virus
was passaged once in C6/36 cells, once in Vero cells, and once in BHK-21
cells prior to cDNA cloning (25).
Virus stocks were generated from cDNAs as described previously (15).
Briefly, plasmids encoding virus cDNAs were linearized by digestion with
SacI. 5=-capped full-length RNA transcripts were generated in vitro using
SP6-specific mMessage mMachine in vitro transcription kits (Ambion).
Full-length transcripts were electroporated into BHK-21 cells using a Bio-
Rad Gene Pulser electroporator. Culture supernatants were harvested at
24 h after electroporation, centrifuged for 20 min at 3,000 rpm (relative
centrifugal force [RCF], 1,721  g), aliquoted, and stored at 80°C. Viral
stocks were titrated by plaque assays on BHK-21 cells.
Construction of virus cDNAs. Plasmid pRR64 (provided by Richard
Kuhn, Purdue University) encodes the full-length cDNA of the T48 strain
of RRV (27). The generation of pRR94 (encoding RRV-T48-nsP1DC5692)
and pRR108 (encoding RRV-DC5692-PE2T48) has been described previ-
ously (25). To generate virus cDNAs with specific mutations in nsP1, a
shuttle vector (pRR90) was created by religation of pRR64 that had been
digested with EcoRI. The six nonsynonymous mutations in the strain
DC5692 nsP1 coding region were introduced sequentially into pRR90 via
site-directed mutagenesis using the QuikChange II XL site-directed mu-
tagenesis kit (Agilent Technologies). Following sequence analysis, pRR90
BssHII-EagI fragments carrying various mutations in nsP1 were inserted
into the BssHII-EagI sites of pRR64. A similar strategy, involving the
sequential introduction of the nonsynonymous T48 strain nsP1 nucleo-
tide changes into a shuttle vector derived from pRR108, followed by sub-
cloning of the BssHII-XbaI fragment, was utilized to generate pRR112,
encoding RRV-DC5692-nsP16M-PE2T48.
Cells. BHK-21 cells (ATCC CCL10) were grown in -minimal essen-
tial medium (Gibco) supplemented with 10% bovine calf serum (Hy-
Clone), 10% tryptose phosphate broth, penicillin and streptomycin, and
0.29 mg/ml L-glutamine. Vero cells (ATCC CCL81) were grown in Dul-
becco’s modified Eagle medium (DMEM)–F-12 medium (Gibco) supple-
mented with 10% fetal bovine serum (FBS) (Lonza), nonessential amino
acids (Gibco), sodium bicarbonate, penicillin and streptomycin, and 0.29
mg/ml L-glutamine. C2C12 murine muscle cells were cultured in DMEM
supplemented with 10% FBS. C2C12 cells were differentiated into myo-
tubes by culturing in fusion medium (DMEM–2% horse serum) for 5 to 6
days. L929 cells were grown in DMEM supplemented with 10% FBS,
penicillin and streptomycin, and 0.29 mg/ml L-glutamine.
Plaque assays. BHK-21 cells or Vero cells were seeded into 6-well
dishes. The growth medium was removed, and cell monolayers were in-
oculated with serial 10-fold dilutions of virus-containing samples. Fol-
lowing a 1-h adsorption at 37°C, cell monolayers were overlaid with 0.5%
immunodiffusion agarose (MP Biomedicals) in medium for 38 to 40 h,
and plaques were visualized by staining with neutral red (Sigma).
Mouse experiments. WT, Rag1/, and Ifng/ C57BL/6J mice were
obtained from The Jackson Laboratory (Bar Harbor, ME) and were bred
in-house. C57BL/6 Ifnar1/ mice were provided by Ken Tyler and Mario
Santiago, University of Colorado School of Medicine. Animal husbandry
and experiments were performed in accordance with all University of
Colorado School of Medicine and University of North Carolina Institu-
tional Animal Care and Use Committee guidelines. Although RRV is clas-
sified as a biosafety level 2 pathogen, due to its exotic nature all mouse
studies were performed in an animal biosafety level 3 laboratory. Unless
otherwise indicated, 3- to 4-week-old mice were used for all in vivo stud-
ies. Mice were inoculated in the left rear footpad with 103 PFU of virus in
a diluent (phosphate-buffered saline [PBS]–1% bovine calf serum) in a
10-l volume. Mock-infected animals received the diluent alone. Mice
were monitored for disease signs and were weighed at 24-h intervals.
Disease scores were determined by assessing grip strength, hind limb
weakness, and altered gait as described previously using the following
system: 1, very mild deficit in hind paw gripping ability of injected foot
only; 2, very mild deficit in bilateral hind paw gripping ability; 3, bilateral
loss of gripping ability and mild bilateral hind limb paresis, but altered gait
not readily observable; 4, bilateral loss of gripping ability, moderate bilat-
eral hind limb paresis, observable altered gait, difficulty righting self; 5,
bilateral loss of gripping ability, severe bilateral hind limb paresis, altered
gait, unable to right self; 6, moribundity (29).
To determine viral titers in tissues, on the termination day of each
experiment, mice were sedated with isoflurane and were euthanized by
thoracotomy and exsanguination; blood was collected; and mice were
perfused by intracardiac injection of 1 PBS. The right and left ankles and
the right and left quadriceps muscles were removed by dissection and were
weighed. Tissues were homogenized with glass beads in 1 PBS supple-
mented with 1% bovine calf serum, Ca2, and Mg2 using a MagNA Lyser
instrument (Roche) and were stored at 80°C until the amount of virus
present was quantified by a standard plaque assay on BHK-21 cells.
To deplete natural killer (NK) cells, 300 g of an anti-NK1.1 antibody
(PK136 mouse IgG2a; a gift of Ron G. Gill, Department of Surgery, Uni-
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versity of Colorado School of Medicine) or PBS was administered by
intraperitoneal (i.p.) injection on day 1 (30).
Reverse transcription-quantitative real-time PCR (RT-qPCR). RRV
RNA was quantified as described previously (29). RNA was isolated using
a PureLink RNA minikit (Life Technologies). Two hundred fifty to 1,000
ng of total RNA was reverse transcribed using SuperScript III reverse
transcriptase (Life Technologies). A sequence-tagged (lowercase letters)
RRV-specific RT primer (starting at position 4415; 5=-ggcagtatcgtgaattcg
atgcAACACTCCCGTCGACAACAGA-3=) was used for reverse transcrip-
tion. A tag sequence-specific reverse primer (5=-GGCAGTATCGTGAAT
TCGATGC-3=) was used with an RRV sequence-specific forward primer
(starting at RRV position 4346; 5=-CCGTGGCGGGTATTATCAAT-3=)
and an internal TaqMan probe (starting at RRV position 4375; 5=-ATTA
AGAGTGTAGCCATCC-3=) during qPCR to enhance specificity. To cre-
ate a standard curve, 10-fold-diluted RRV genomic RNA (from 108 to 100
copies), synthesized in vitro, was spiked into RNA from BHK-21 cells, and
reverse transcription and qPCR were performed in an identical manner.
Flow cytometry. Splenocytes were incubated with anti-mouse
FcRII/FcRIII (2.4G2; BD Pharmingen) for 20 min on ice to block non-
specific antibody binding and were then stained in fluorescence-activated
cell sorting (FACS) staining buffer (1 PBS, 2% FBS) with the following
antibodies from eBioscience: fluorescein isothiocyanate (FITC)-conju-
gated anti-CD3ε and phycoerythrin (PE)-conjugated anti-CD49b. Cells
were fixed overnight in 1% paraformaldehyde, and data were acquired on
an LSR II flow cytometer using FACSDiva software. FlowJo software
(TreeStar) was used for all analyses.
Type I IFN ELISA and bioassay. Alpha interferon (IFN-) and IFN-
were measured in sera by using a mouse IFN- enzyme-linked immu-
nosorbent assay (ELISA) (Pestka Biomedical Laboratories) (31) or a bio-
logical assay as described previously (32, 33). For the bioassay, L929 cells
(ATCC CCL-1) were seeded in 96-well plates. Mouse sera and a type I IFN
standard (murine IFN-; BEI Resources), both diluted in L929 medium,
were acidified to a pH of 2.0 for 24 h and were then neutralized to a pH
of 7, treated with UV light for 10 min to inactivate residual virus, and
added to cells in serial 2-fold dilutions. The following day, encephalomyo-
carditis virus (EMCV) was added to cells at a multiplicity of infection
(MOI) of 5. Twenty-four hours later, cell viability was determined by
staining monolayers with crystal violet, solubilizing the absorbed crystal
violet in methanol, and measuring the absorbance at 570 nm. The type I
IFN present in each sample (IU/ml) was calculated by determining the
dilution of the IFN standard and of each sample that conferred 50% pro-
tection from EMCV-induced cytopathic effects. Wells that received no
IFN and no EMCV served as the “cell control,” the control for 100%
protection. Wells that received EMCV and no IFN provided the control
for 0% protection.
In vitro virus replication. Triplicate wells were inoculated with virus
at an MOI of 0.01. Viruses were adsorbed onto cells for 1 h at 37°C. Wells
were then washed three times with 1 ml of room temperature PBS. One
milliliter of growth medium was then added to each well, and cells were
incubated at 37°C. For cumulative growth analysis, 100-l samples of
culture supernatants were removed at various times postinfection, and an
equal volume of fresh growth medium was added to maintain a constant
volume within each well. Samples were stored at 80°C for analysis by
plaque assays on BHK-21 cells.
Assays of sensitivity to type I IFN. Vero cells or differentiated C2C12
cells were plated in 96-well plates or 24-well plates, respectively. The
growth medium was removed, and triplicate wells were inoculated with
virus at the MOIs indicated in the figure legends. Viruses were adsorbed to
cells for 1 h at 37°C. Wells were then washed with three changes of room
temperature 1 PBS. Growth medium was then added to each well, and
cells were incubated at 37°C. At 3 h postinoculation (hpi), growth me-
dium containing either no IFN- or 2 to 250 IU/ml of human or murine
IFN- (BEI Resources) was added to the wells. At 48 hpi, supernatants
were collected, and virus titers were determined by plaque assays on
BHK-21 cells. In some experiments, Vero cells were pretreated with hu-
man IFN- for 24 h prior to the inoculation of virus at an MOI of 5. At 24
hpi, supernatants were collected, and virus titers were determined by
plaque assays on BHK-21 cells.
Statistical analysis. Viral replication and tissue titers were evaluated
for statistically significant differences by using either the Student t test or
one-way analysis of variance (ANOVA) followed by Tukey’s multiple-
comparison test. Disease scores were evaluated for statistically significant
differences by repeated-measures ANOVA followed by Bonferroni’s mul-
tiple-comparison test.
RESULTS
Coding variants in nsP1 are determinants of RRV virulence. In
previous studies, we found that a chimeric virus containing the
nsP1 coding region from the mouse-avirulent RRV strain DC5692
in the genetic background of the mouse-virulent strain T48 (RRV-
T48-nsP1DC5692) caused diminished inflammation in musculosk-
eletal tissues and significantly less severe musculoskeletal disease
signs in mice (25). Comparison of the nsP1 coding regions of
strain T48 and strain DC5692 revealed a total of 36 nucleotide
differences (25). Six of these nucleotide differences are nonsyn-
onymous and result in the following amino acid coding changes in
the nsP1 sequence: S79C, A112S, L224I, C416F, S424N, and
L463I. To test whether the nonsynonymous mutations were suf-
ficient to attenuate strain T48, the six DC6592 nsP1 coding vari-
ants were introduced into the nsP1 coding region of strain T48
(RRV-T48-nsP16M) (Fig. 1A). As with RRV-T48-nsP1DC5692,
which contains the complete DC5692 nsP1 coding region in the
T48 strain genetic background (Fig. 1A), inoculation of mice with
RRV-T48-nsP16M (Fig. 1A) resulted in significantly less severe
disease signs (Fig. 1B [P, 	0.01 for RRV T48 versus RRV-T48-
nsP1DC5692 and 	0.05 for RRV T48 versus RRV-T48-nsP16M] and
C). These findings indicated that the six nonsynonymous muta-
tions in nsP1 derived from strain DC5692 are sufficient for the
attenuated phenotype. We next tested whether replacement of the
six nsP1 coding variants in strain DC5692 with the nonsynony-
mous nucleotides from strain T48 would result in a gain of viru-
lence. As reported previously, replacement of the strain DC5692
nsP1 and PE2 coding regions with those from strain T48 was re-
quired to confer full virulence on the mouse-avirulent strain
DC5692 (25). Thus, we introduced the six T48 nsP1 coding vari-
ants into a chimeric RRV genome that carries the T48 PE2 coding
region in the genetic background of strain DC5692 (RRV-
DC5692-PE2T48) to generate RRV-DC5692-nsP16M-PE2T48 (Fig.
1A). In agreement with previously reported findings (25), inocu-
lation of mice with RRV-DC5692-PE2T48 (previously referred to
as RR108) resulted in significantly less severe disease signs in mice
(Fig. 1D and E). In contrast, inoculation of mice with RRV-
DC5692-nsP16M-PE2T48 resulted in disease signs and tissue pa-
thology that were indistinguishable from those for RRV T48-in-
oculated mice (Fig. 1D and E).
To investigate whether the attenuated phenotype of RRV-T48-
nsP16M in WT mice was associated with differences in viral loads
in tissues, mice were inoculated with RRV T48 or RRV-T48-
nsP16M, and the amounts of infectious virus present in serum,
ankle/foot tissues, and quadriceps muscle tissues at 1, 3, 5, and 7
dpi were quantified by plaque assays (Fig. 2). In agreement with
our previously published studies finding that viral loads in mice
inoculated with RRV T48 or RRV-T48-nsP1DC5692 were similar
(25), the amounts of infectious virus in the sera (Fig. 2A), ankles/
feet (Fig. 2B and C), and quadriceps muscles (Fig. 2D and E) of
RRV T48-inoculated mice at 1, 3, and 5 dpi did not generally
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exceed those for RRV-T48-nsP16M-inoculated mice. At 7 dpi, the
titers of RRV-T48-nsP16M in both the left and right ankles were
significantly lower than those of RRV T48 (9.8-fold [P, 	0.001]
and 5.1-fold [P, 	0.05], respectively) (Fig. 2B and C).
RRV-T48-nsP16M is attenuated in Rag1/ mice. Our exper-
iments with WT mice indicated that RRV-T48-nsP16M had an
impact on weight gain (relative to the weight gain of mock-in-
fected mice) similar to that of the virulent strain RRV T48 from
days 1 to 6 postinoculation (Fig. 1B). From 6 to 10 dpi, mice
inoculated with RRV-T48-nsP16M continued to gain weight at a
rate similar to that of mock-infected mice, consistent with the
minimal musculoskeletal disease signs (Fig. 1C), whereas mice
inoculated with RRV T48 showed significantly reduced weight
gain during this time frame (Fig. 1B). In addition, the viral loads in
the tissues of WT mice inoculated with these viruses were similar
until 7 dpi (Fig. 2). On the basis of these data, we hypothesized that
RRV-T48-nsP16M is more susceptible to some aspect of the adap-
tive immune response, which typically arises at 
1 week post-
virus infection. To test this hypothesis, Rag1/ C57BL/6 mice,
which lack mature T and B lymphocytes due to an inability to
perform V(D)J recombination of immunoglobulin and T cell re-
ceptor genes (34), were inoculated with RRV T48 or RRV-T48-
nsP16M and were monitored for the development of disease signs.
As shown in Fig. 3A and B, inoculation of Rag1/ mice with
RRV-T48-nsP16M resulted in disease signs significantly less severe
than those of Rag1/ mice inoculated with RRV T48.
FIG 1 Coding variants in nsP1 are determinants of RRV virulence. (A) Schematic representations of the genomes of the Ross River viruses used in this study.
Open rectangles, sequences derived from the mouse-virulent strain T48; shaded rectangles, sequences derived from the mouse-avirulent strain DC5692. (B and
C) Three- to 4-week-old C57BL/6 mice were inoculated either with PBS (n  7) or with 103 PFU of RRV T48 (n  12), RRV-T48-nsP1DC5692 (n  8), or
RRV-T48-nsP16M (n  9) by injection in the left rear footpad. At 24-h intervals, mice were assessed for weight gain (B) and were scored for musculoskeletal
disease signs, including loss of gripping ability and altered gait (C). Each data point represents the arithmetic mean  standard error of the mean. Data were
evaluated for statistically significant differences by a repeated-measures ANOVA followed by Bonferroni’s multiple-comparison test. *, P 	 0.05; **, P 	 0.01.
(D and E) Three- to 4-week-old C57BL/6 mice were inoculated with 103 PFU of RRV T48 (n  7), RRV-DC5692-PE2T48 (n  8), or RRV-DC5692-nsP16M-
PE2T48 (n  11) by injection in the left rear footpad. At 24-h intervals, mice were assessed for weight gain (D) and were scored for musculoskeletal disease signs,
including loss of gripping ability and altered gait (E). Each data point represents the arithmetic mean  standard error of the mean. Data were evaluated for
statistically significant differences by a repeated-measures ANOVA followed by Bonferroni’s multiple-comparison test. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001.
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To investigate whether the attenuated phenotype of RRV-T48-
nsP16M in Rag1/ mice was associated with differences in viral
loads in tissues, Rag1/ mice were inoculated with RRV T48 or
RRV-T48-nsP16M, and the amounts of infectious virus present in
sera, ankle/foot tissues, and quadriceps muscle tissues at 1, 3, 5,
and 7 dpi were quantified by plaque assays (Fig. 4). The titers of
RRV-T48-nsP16M in sera were significantly higher than the titers
of RRV T48 at 3 dpi (4.8-fold [P, 	0.01]) and 5 dpi (8.6-fold [P,
	0.001]) (Fig. 4A). In contrast to the findings for WT mice, no
differences in viral titers were detected in ankle/foot tissues at the
time points analyzed (Fig. 4B and C). The titers of RRV-T48-
nsP16M in both the left and right quadriceps muscle tissues were
similar to those of RRV T48 at 1 and 3 dpi (Fig. 4D and E). How-
ever, by 5 dpi, the titers of RRV-T48-nsP16M in both the left and
right quadriceps muscle tissues were significantly lower than those
of RRV T48 (7-fold [P, 	0.01] and 6.2-fold [P, 	0.01], respec-
tively). By 7 dpi, the differences in the viral titers in the left and
right quadriceps muscles were more dramatic (54-fold [P,
	0.001] and 10.2-fold [P, 	0.001], respectively). In fact, at 7 dpi,
infectious virus was detectable in 14 of 14 quadriceps muscles of
mice inoculated with RRV T48, whereas only 2 of 14 quadriceps
muscles of mice inoculated with RRV-T48-nsP16M had detectable
infectious virus (Fig. 4D and E).
To confirm these data, we quantified the RRV RNA present in
the right quadriceps muscles of RRV T48- and RRV-T48-nsP16M-
FIG 3 RRV-T48-nsP16M is attenuated in Rag1/ mice. Three- to 4-week-old
Rag1/ C57BL/6 mice were inoculated with 103 PFU of RRV T48 (n  5) or
RRV-T48-nsP16M (n  6) by injection in the left rear footpad. At 24-h intervals,
mice were assessed for weight gain (A) and were scored for musculoskeletal disease
signs, including loss of gripping ability and altered gait (B). Each data point repre-
sents the arithmetic mean  standard error of the mean. Data were evaluated for
statistically significant differences by a repeated-measures ANOVA followed by
Bonferroni’s multiple-comparison test. **, P 	 0.01; ***, P 	 0.001.
FIG 2 Infectious virus in tissues of WT mice. Three- to 4-week-old C57BL/6 mice were inoculated with 103 PFU of RRV T48 (filled circles) or RRV-T48-nsP16M (open
circles) by injection in the left rear footpad. At 1, 3, 5, and 7 dpi, mice (n, 5 to 11) were sacrificed, blood was collected via cardiac puncture, and mice were perfused by
intracardial injection with 1 PBS. Tissues were dissected, weighed, and homogenized, and the amounts of infectious virus present in the serum (A), left ankle/foot (B),
right ankle/foot (C), left quadriceps muscle (D), and right quadriceps muscle (E) of each mouse were quantified by plaque assays on BHK-21 cells. Dashed lines indicate
the limits of detection. Asterisks indicate significant differences (*, P 	 0.05; ***, P 	 0.001) as determined by ANOVA followed by Tukey’s multiple-comparison test.
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infected Rag1/ mice at 3, 5, and 7 dpi by real-time RT-qPCR. At
3 dpi, we detected a small but significant increase in the level of
RRV RNA in the right quadriceps muscles of mice inoculated with
RRV-T48-nsP16M (2.5-fold [P, 	0.01]) (Fig. 5A). However, at
both 5 and 7 dpi, RRV RNA levels in the right quadriceps were
dramatically lower in RRV-T48-nsP16M-infected mice than in
RRV T48-infected mice (22.8-fold [P, 	0.001] and 71.8-fold [P,
	0.001], respectively) (Fig. 5A). The differences in RNA levels
were similar whether we calculated the quantity of RRV genomes
per microgram of RNA (Fig. 5A) or per gram of tissue (data not
shown). To explore whether our analysis of infectious virus pres-
ent in quadriceps muscle tissues of WT mice was misleading due
to the potential presence of antiviral antibodies and/or the fact
that titers at 5 and 7 dpi were near or below the limit of detection
(Fig. 2D and E), we quantified the RRV RNA present in the right
quadriceps muscles of RRV T48- and RRV-T48-nsP16M-infected
WT mice at 3, 5, and 7 dpi. As with Rag1/ mice, the levels of
RRV RNA were similar at 3 dpi but dramatically reduced in mice
inoculated with RRV-T48-nsP16M at both 5 and 7 dpi (91.2-fold
[P, 	0.001] and 30-fold [P, 	0.001], respectively) (Fig. 5B). In
contrast, at 7 dpi, the levels of RRV RNA in the left (Fig. 5C) and
right (Fig. 5D) ankles of WT mice inoculated with RRV T48 or
RRV-T48-nsP16M were similar. Taken together, our findings for
WT and Rag1/ mice suggest that the attenuating mutations in
nsP1 of RRV-T48-nsP16M render the virus more susceptible to
tissue-specific host antiviral responses.
Depletion of NK cells or deletion of IFN- does not rescue
RRV-T48-nsP16M loads in skeletal muscle tissue. The timing of
the differences in the loads of RRV T48 and RRV-T48-nsP16M in
the skeletal muscle tissue of WT and Rag1/ mice (Fig. 4 and 5)
correlated with the infiltration of this tissue with natural killer
(NK) cells and macrophages (15). To test if the reduced loads of
RRV-T48-nsP16M in skeletal muscle tissue were due to the antivi-
ral activity of NK cells, 300 g of an anti-NK1.1 monoclonal an-
tibody was administered intraperitoneally to WT (Fig. 6A to C) or
Rag1/ (Fig. 6D to F) mice 1 day before inoculation with RRV-
T48-nsP16M. At 5 dpi, the levels of RRV-T48-nsP16M RNA present
in the right quadriceps muscles of WT (Fig. 6A) or Rag1/ (Fig.
6D) mice treated with the anti-NK1.1 antibody were similar to
those in PBS-injected control mice. In addition, the RRV-T48-
nsP16M RNA levels in WT and Rag1/ mice treated with the
anti-NK1.1 antibody were similar to those detected in untreated
RRV-T48-nsP16M-infected mice and remained dramatically
lower than the RRV RNA levels in skeletal muscle tissues of RRV
T48-infected mice (Fig. 6A and D; graphed from Fig. 5 for com-
parison). Flow cytometric analysis of splenocytes harvested at 5
dpi from WT (Fig. 6B and C) or Rag1/ (Fig. 6E and F) mice
confirmed that administration of the anti-NK1.1 antibody signif-
icantly reduced the number of CD3 CD49b NK cells. The pro-
duction of IFN- by NK cells and other cell types contributes to
antiviral defense (35). To evaluate if the reduced loads of RRV-
T48-nsP16M in skeletal muscle tissue were due to the effects of
FIG 4 Infectious virus in tissues of Rag1/ mice. (A to E) Three- to 4-week-old Rag1/ C57BL/6 mice were inoculated with 103 PFU of RRV T48 (filled circles)
or RRV-T48-nsP16M (open circles) by injection in the left rear footpad. At 1, 3, 5, and 7 dpi, mice (n, 4 to 7) were sacrificed, blood was collected via cardiac
puncture, and mice were perfused by intracardial injection with 1 PBS. Tissues were dissected, weighed, and homogenized, and the amounts of infectious virus
present in the serum (A), left ankle/foot (B), right ankle/foot (C), left quadriceps muscle (D), and right quadriceps muscle (E) of each mouse were quantified by
plaque assays on BHK-21 cells. Dashed lines indicate the limits of detection. Asterisks indicate significant differences (**, P 	 0.01; ***, P 	 0.001) as determined
by ANOVA followed by Tukey’s multiple-comparison test.
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IFN-, we inoculated C57BL/6 mice deficient in IFN- (Ifng/)
with RRV T48 or RRV-T48-nsP16M and quantified the RRV RNA
present in the right quadriceps muscles at 5 dpi by real-time RT-
qPCR. As with WT and Rag1/ mice, RRV RNA levels in the
right quadriceps were dramatically lower in RRV-T48-nsP16M-
infected Ifng/ mice than in RRV T48-infected Ifng/ mice
(328-fold [P, 	0.0001]) (Fig. 6G). Taken together, these data sug-
gest that the attenuating mutations in nsP1 of RRV-T48-nsP16M
do not render the virus more susceptible to NK cell-mediated
clearance or to the antiviral effects of IFN-.
Attenuating mutations in nsP1 enhance sensitivity to type I
IFN. Overall, our analyses revealed that the attenuating mutations
in nsP1 enhanced host control of RRV infection in skeletal muscle
tissues, but not in ankle/foot tissues or sera, of WT and Rag1/
mice, suggesting that RRV-T48-nsP16M is more susceptible to
some aspect of the host’s innate antiviral response in skeletal mus-
cle tissues and likely explaining the attenuated disease signs. How-
ever, depletion of NK cells or genetic deletion of IFN- failed to
rescue loads of the nsP1 mutant virus in skeletal muscle tissue.
Type I IFN is a component of the host’s innate antiviral response
and a critical regulator of alphavirus replication, spread, and vir-
ulence (36). To test whether RRV T48 and RRV-T48-nsP16M are
equally virulent in the absence of the effects of type I interferon, we
inoculated Ifnar1/ C57BL/6 mice with 1,000 PFU of RRV T48
or RRV-T48-nsP16M and monitored the mice for survival. As
shown in Fig. 7A, RRV T48 and RRV-T48-nsP16M were equally
virulent in 3- to 4-week-old Ifnar1/ mice; all mice were mori-
bund by 40 to 44 h postinoculation. Due to the rapid time to
morbidity in mice of this age, we were unable to evaluate viral
loads in quadriceps muscle tissue at later times postinoculation.
To that end, we tested the extent to which inoculation of older
Ifnar1/ mice with lower doses of virus would increase survival
time. We found that inoculation of 12- to 14-week-old Ifnar1/
mice with 5 PFU of virus extended the time to morbidity until 4
dpi. As shown in Fig. 7B, RRV RNA levels in the left and right
quadriceps of Ifnar1/ mice at 4 dpi were slightly lower in RRV-
T48-nsP16M-infected mice than in RRV T48-infected mice (4-fold
and 6-fold, respectively); however, these differences were not sta-
tistically significant. Although it remains possible that these dif-
ferences in viral loads would be exacerbated at 5 dpi, taken to-
gether, our data suggest that the attenuating mutations in nsP1 of
RRV-T48-nsP16M render the virus more susceptible to the type I
IFN response in skeletal muscle tissue.
We next investigated if RRV-T48-nsP16M is a more potent in-
ducer of type I IFN and/or is more sensitive to antiviral effector
functions activated by type I IFN. At 24 hpi, despite equivalent
viral loads in sera and other tissues (Fig. 2), we detected signifi-
cantly more IFN- in the sera of RRV T48-infected WT mice than
in the sera of RRV-T48-nsP16M-infected WT mice (Fig. 7C) (P,
	0.001). However, at 12, 48, 72, and 120 hpi, similar levels of
systemic IFN- were detected in the sera of RRV T48-infected and
RRV-T48-nsP16M-infected WT mice (Fig. 7C). Similar results
were observed at 48 hpi by use of a type I IFN bioassay (data not
shown). These data suggest that the attenuated phenotype of
RRV-T48-nsP16M is not due to enhanced induction of systemic
type I interferon.
In vitro, virus yields from Vero cells and differentiated C2C12
murine muscle cells inoculated with RRV T48 or RRV-T48-
nsP16M at a low MOI (0.01) were similar at 6, 12, 24, and 48 hpi
(Fig. 8A and B), indicating that these two cell lines could be uti-
lized to test the effects of exogenous IFN on virus replication. To
test whether RRV-T48-nsP16M is more sensitive to type I IFN,
Vero cells, which respond to type I IFN but cannot produce type I
IFN (37, 38), were inoculated with RRV T48 or RRV-T48-nsP16M
FIG 5 RRV RNA levels in tissues of Rag1/ and WT mice. Three- to 4-week-
old Rag1/ (A) or WT (B to D) C57BL/6 mice were inoculated with 103 PFU
of RRV T48 (filled circles) or RRV-T48-nsP16M (open circles) by injection in
the left rear footpad. At 3, 5, and 7 dpi, mice were sacrificed and were perfused
by intracardial injection with 1 PBS, and total RNA was isolated from the
right quadriceps muscles (A and B), the left ankle (C), and the right ankle (D).
RRV genomic RNA was quantified by RT-qPCR. Horizontal bars indicate
means, and dashed lines indicate the limits of detection. Asterisks indicate
significant differences (**, P 	 0.01; ***, P  0.001) as determined by ANOVA
followed by Tukey’s multiple-comparison test.
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FIG 6 Depletion of NK cells or deletion of IFN- fails to restore RRV-T48-nsP16M loads in skeletal muscle tissue. (A to F) Three- to 4-week-old WT (A to C) or
Rag1/ (D to F) C57BL/6 mice were injected i.p. with PBS or 300 g of an anti-NK1.1 antibody on day 1. On day zero, mice were inoculated with 103 PFU
of RRV-T48-nsP16M by injection in the left rear footpad. (A and D) At 5 dpi, WT (A) or Rag1/ (D) mice were sacrificed and were perfused with PBS via
intracardiac injection with 1 PBS, and RRV RNA in the right quadriceps muscle was quantified by RT-qPCR. Levels of RRV RNA in untreated mice infected
with RRV T48 or RRV-T48-nsP16M were graphed for comparison. Horizontal bars indicate means. Asterisks indicate significant differences (***, P  0.001) as
determined by ANOVA followed by Tukey’s multiple-comparison test. (B and E) Total splenocytes from WT (B) and Rag1/ (E) mice were analyzed by flow
cytometry for the expression of CD49b. Representative contour plots are shown. SSC, side scatter. (C and F) Percentages of CD49b cells in the spleens of WT
(C) and Rag1/ (F) mice. Each bar represents the arithmetic mean  standard error of the mean. P values were determined using two-tailed unpaired t tests.
(G) Three- to 4-week-old Ifng/ C57BL/6 mice were inoculated with 103 PFU of RRV T48 or RRV-T48-nsP16M by injection in the left rear footpad. At 5 dpi,
mice were sacrificed and were perfused with PBS via intracardiac injection with 1 PBS, and RRV RNA in the right quadriceps muscle was quantified by
RT-qPCR. Horizontal bars indicate means. The P value was determined by a two-tailed unpaired t test.
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at a low MOI (0.1 PFU/cell). At 3 hpi, cells either were mock
treated or were treated with various amounts of IFN-, and virus
yields in the culture supernatants at 48 hpi were quantified by
plaque assays. As shown in Fig. 8C, RRV-T48-nsP16M showed
higher sensitivity to IFN- treatment than RRV T48 (19.5-fold
and 295-fold decreases in virus yields at 16 IU/ml and 32 IU/ml of
IFN-, respectively [P, 	0.05 and 	0.001, respectively]). Simi-
larly, RRV-T48-nsP16M showed higher sensitivity to IFN- treat-
ment than RRV T48 in differentiated C2C12 murine myoblasts
(Fig. 8D) (8.5-fold and 42-fold decreases in virus yields at 50
IU/ml and 250 IU/ml IFN-, respectively [P, 	0.001]). RRV-T48-
nsP16M also showed increased sensitivity to IFN- when Vero cells
were pretreated with IFN- for 24 h and were then inoculated at a
high MOI (5 PFU/cell) (6-fold decrease at 32 IU/ml IFN- [P,
	0.05]) (Fig. 8E). Overall, the attenuating mutations in nsP1 ap-
pear to enhance the sensitivity of RRV to type I IFN in vitro, and
RRV-T48-nsP16M virulence and loads in skeletal muscle tissue are
restored in vivo in mice unable to respond to type I IFN.
The attenuated phenotype requires two nsP1 coding changes.
To determine whether the attenuated phenotype of RRV-T48-
nsP16M could be attributed to a single coding change, each non-
synonymous mutation found in RRV DC5692 nsP1 was individ-
ually introduced into the cDNA clone of strain RRV T48, and the
abilities of viruses derived from these clones to cause disease in the
mouse model were tested. As shown in Fig. 9A and B, inoculation
of groups of WT mice with 103 PFU of each virus revealed that no
single mutation fully recapitulated the attenuated phenotype ob-
served in WT mice inoculated with RRV-T48-nsP16M (Fig. 1B and
C). However, mice inoculated with either RRV-T48-nsP1-S79C
or RRV-T48-nsP1-L224I developed significantly milder disease
signs than mice inoculated with RRV T48 (Fig. 9B). Therefore, we
constructed a double mutant virus carrying both of these muta-
tions in nsP1. Both by weight gain measurements (Fig. 9C) and by
scoring of musculoskeletal disease signs (Fig. 9D), RRV-T48-
nsP1-S79C;L224I was attenuated in WT mice to a similar level as
RRV-T48-nsP16M, suggesting that these two DC5692 nsP1 coding
variants are sufficient for the attenuated phenotype.
Our experiments with RRV-T48-nsP16M suggested that the at-
tenuated phenotype in mice may be due to increased sensitivity to
type I IFN (Fig. 8). To investigate if RRV-T48-nsP1-S79C;L224I
also has enhanced sensitivity to type I IFN, we compared the type
I IFN sensitivity of RRV-T48-nsP1-S79C;L224I to those of both
RRV T48 and RRV-T48-nsP16M in Vero cells. As shown in Fig.
9E, RRV-T48-nsP16M and RRV-T48-nsP1-S79C;L224I showed
higher sensitivity to IFN- treatment than RRV T48 (234-fold,
98-fold, and 18.2-fold decreases in virus yields at 32 IU/ml of
IFN-, respectively P, 	0.001 and 	0.01, respectively).
DISCUSSION
Identification of virulence determinants within nsP1. To deter-
mine which of the nucleotide differences in nsP1 between RRV
T48 and DC5692 were responsible for the attenuated disease phe-
notype of RRV-T48-NSP1DC5692 (25), we introduced the six
DC5692 nsP1 coding variants into the mouse-virulent RRV T48
genome to create RRV-T48-nsP16M. We found that, in compari-
son to infection with RRV T48, RRV-T48-nsP1DC5692 and RRV-
T48-nsP16M were equally attenuated in the mouse model, indicat-
ing that the six coding changes within the nsP1 sequence were
sufficient for the attenuated phenotype. Furthermore, introduc-
tion of the six RRV T48 nsP1 coding variants into the attenuated
RRV-DC5692-PE2T48 strain resulted in a gain of virulence, con-
firming that these nsP1 mutations are determinants of RRV viru-
lence. Introduction of the six DC5692 nsP1 coding variants indi-
vidually into the RRV T48 genetic background failed to reproduce
the attenuated phenotype of RRV-T48-nsP16M, indicating that
attenuation was not due to a single point mutation. However, the
disease signs in mice inoculated with either RRV-T48-nsP1-S79C
or RRV-T48-nsP1-L224I were significantly less severe than those
in RRV T48-infected mice. Thus, we generated a mutant virus
containing both these mutations (RRV-T48-nsP1-S79C;L224I)
and observed an attenuated phenotype similar to that of RRV
T48-nsP16M, indicating that these are the major attenuating mu-
tations within nsP1.
The nsP1 protein of alphaviruses is a replicase protein of 534 to
540 amino acids that functions in viral RNA replication and viral
FIG 7 Virulence and RRV RNA levels in Ifnar1/ mice. (A) Three- to
4-week-old Ifnar1/ C57BL/6 mice were inoculated with 103 PFU of RRV
T48 (filled circles) or RRV-T48-nsP16M (open circles) by injection in the left
rear footpad, and mice were monitored for survival. (B) Twelve- to 14-week-
old Ifnar1/ C57BL/6 mice were inoculated with 5 PFU of RRV T48 (filled
circles) or RRV-T48-nsP16M (open circles) by injection in the left rear footpad.
At 4 dpi, mice were sacrificed and were perfused by intracardial injection with
1 PBS, and RRV genomic RNA in the quadriceps muscles was quantified by
RT-qPCR. Horizontal bars indicate means. No statistically significant differ-
ences were detected by two-tailed unpaired t tests. (C) Three- to 4-week-old
WT C57BL/6 mice were either mock inoculated or inoculated with 103 PFU of
RRV T48 or RRV-T48-nsP16M by injection in the left rear footpad. At 12 (n, 5
mice/group), 24 (n, 4 to 5 mice/group), 48 (n, 4 mice/group), 72 (n, 7 to 8
mice/group), and 120 (n, 10 mice/group) hpi, mice were sacrificed, blood was
collected via cardiac puncture, and the amount of IFN- was quantified by
ELISA.
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RNA capping (39). The capping activities of nsP1 are essential for
viral replication (40). The structure of nsP1 is unknown, and stud-
ies have failed to define specific enzymatic subdomains. Analysis
of purified recombinant nsP1 by circular dichroism revealed that
a high percentage of nsP1 residues are in disordered regions and
not in the regular secondary structure (41). It was postulated that
these disordered regions may participate in specific interactions
with other proteins, nucleic acids, or membranes (41). Due to the
lack of information regarding the structure of nsP1, the roles of
amino acid positions 79 and 224 in nsP1 structure-function are
unclear. Amino acid sequence alignments of nsP1 proteins of al-
phaviruses in the Semliki Forest antigenic complex, which in-
cludes RRV, CHIKV, Semliki Forest virus (SFV), Mayaro virus,
and o’nyong-nyong virus, revealed that positions 79 and 224 are in
highly conserved regions of the nsP1 sequence (see Table S1 in the
supplemental material). In all sequences analyzed, a cysteine was
present at position 79, including two entries for the RRV T48
sequence (GenBank accession no. GQ433359 and DQ226993).
However, the RRV T48 sequence encoded in the pRR64 plasmid,
which was generated from RRV T48 obtained from the Yale Ar-
bovirus Research Unit (26), has a serine at nsP1 position 79, sug-
gesting that this mutation may be the result of repeated passages in
mice prior to cDNA cloning of the viral genome (26, 27). Except in
RRV strains DC5692 (GenBank accession no. HM234643) and
NB5092 (GenBank accession no. M20162), all nsP1 sequences an-
alyzed have a leucine at nsP1 position 224. Like RRV DC5692,
RRV NB5092 has an isoleucine at nsP1 position 224 and is atten-
uated in mice (25, 42).
In studies of temperature-sensitive (ts) mutants of SFV and
Sindbis virus (SINV), only three ts mutations (D119N, E529D,
and A348T), have been mapped to nsP1. Each of these mutants is
specifically defective in minus-strand RNA synthesis, demonstrat-
ing an important role for nsP1 in RNA replication (43, 44). Al-
though the three ts mutations of nsP1 cause similar defects in
minus-strand synthesis, they are located in different parts of the
primary sequence of the protein (43). The nsP1 protein also has
guanine-7-methyltransferase and guanylyltransferase activities,
which are essential for capping and cap methylation of viral RNAs
by mechanisms that are distinct from host RNA-capping mecha-
nisms (45–48). The N terminus of nsP1 is predicted to function as
FIG 8 Attenuating mutations in nsP1 enhance the sensitivity of RRV to type I IFN. (A and B) Vero cells (A) or differentiated C2C12 murine muscle cells (B) were
inoculated with RRV T48 or RRV-T48-nsP16M at an MOI of 0.01. At 0 hpi (input) and 12, 24, and 48 hpi, the amounts of infectious virus present in culture
supernatants were quantified by plaque assays. (C) Virus yields at 48 hpi in Vero cells treated with increasing doses of IFN- 3 h after infection with RRV T48 or
RRV-T48-nsP16M (MOI, 0.1). Asterisks indicate significant differences (*, P 	 0.05; ***, P 	 0.001) as determined by ANOVA followed by Tukey’s multiple-
comparison test. (D) Virus yields at 48 hpi in differentiated C2C12 cells treated with increasing doses of IFN- 3 h after infection with RRV T48 or RRV-T48-
nsP16M (MOI, 1). Asterisks indicate significant differences (***, P 	 0.001) as determined by ANOVA followed by Tukey’s multiple-comparison test. (E) Virus
yields at 24 hpi in Vero cells treated with increasing doses of IFN- 24 h prior to infection with RRV T48 or RRV-T48-nsP16M (MOI, 5). The asterisk indicates
a significant difference (*, P 	 0.05) as determined by ANOVA followed by Tukey’s multiple-comparison test.
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the methyltransferase, and specific mutations that affect the bind-
ing of enzymatic substrates have been located in the first 310
amino acids of nsP1. For example, two conserved acidic residues,
D62 and D88 in RRV nsP1, are essential for S-adenosyl-L-methi-
onine binding (46). In addition, mutations in the N terminus of
nsP1 (R87L and S88C) of SINV increased the affinity of nsP1 for
S-adenosyl-L-methionine (48), and mutations at nsP1 residues 23
and 302 were selected during SINV replication in the presence of
decreased levels of GTP, likely increasing the affinity of nsP1 for
GTP (49). These studies indicate that specific mutations can mod-
ulate nsP1 methyltransferase and guanylyltransferase activities. As
discussed further below, we hypothesize that the attenuating mu-
FIG 9 Mapping studies. (A and B) Three- to 4-week-old WT C57BL/6 mice were inoculated with 103 PFU of RRV T48 (n  8), RRV-T48-nsP1-S79C (n  4),
RRV-T48-nsP1-A112S (n  3), RRV-T48-nsP1-L224I (n  8), RRV-T48-nsP1-C416F (n  7), RRV-T48-nsP1-S424N (n  4), or RRV-T48-nsP1-L463I (n 
4) by injection in the left rear footpad. At 24-h intervals, mice were assessed for weight gain (A) and were scored for musculoskeletal disease signs, including loss
of gripping ability and altered gait (B). Each data point represents the arithmetic mean  standard error of the mean. Data were evaluated for statistically
significant differences by a repeated-measures ANOVA followed by Bonferroni’s multiple-comparison test. *, P 	 0.05; **, P 	 0.01. (C and D) Three- to
4-week-old WT C57BL/6 mice were inoculated with 103 PFU of RRV T48 (n  11) or RRV-T48-nsP1-S79C;L224I (n  10) by injection in the left rear footpad.
At 24-h intervals, mice were assessed for weight gain (C) and were scored for musculoskeletal disease signs, including loss of gripping ability and altered gait (D).
Each data point represents the arithmetic mean  standard error of the mean. Data were evaluated for statistically significant differences by a repeated-measures
ANOVA, followed by Bonferroni’s multiple-comparison test. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001. (E) Virus yields at 48 hpi in Vero cells either left untreated
or treated with 32 IU/ml of IFN- 3 h after infection with RRV T48, RRV-T48-nsP16M, or RRV-T48-nsP1-S79C;L224I (MOI, 0.1). Asterisks indicate significant
differences (**, P 	 0.01; ***, P 	 0.001) as determined by ANOVA followed by Tukey’s multiple-comparison test.
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tations in nsP1 identified in this study modulate nsP1 function in
RNA synthesis and/or capping activity in a manner that increases
the effectiveness of IFN-stimulated antiviral effectors. Intrigu-
ingly, however, these effects appear to be operative in skeletal
muscle tissue but not in joint-associated tissues. Alternatively, it is
possible that the attenuating mutations in nsP1 affect some aspect
of nonstructural polyprotein processing and the release of free
nsP2, which plays important roles in counteracting the IFN re-
sponse to alphavirus infection (50–52). However, previously pub-
lished studies suggested that the kinetics of nonstructural poly-
protein processing by RRV T48 and RRV-T48-nsP1DC5692,
though not tested in cells, were similar in an in vitro translation
assay (25). Thus, further studies are needed to determine the pre-
cise mechanisms by which these mutations in nsP1 contribute to
RRV virulence.
Attenuating mutations in nsP1 reveal that host control of
RRV infection is tissue specific. Based on our experiments in WT
mice, which indicated that the amounts of infectious virus in the
tissues of mice inoculated with RRV T48 and RRV-T48-nsP16M
were similar until 7 dpi, we hypothesized that RRV-T48-nsP16M
was more susceptible to some aspect of the adaptive immune re-
sponse. However, measurements of weight gain and musculosk-
eletal disease signs indicated that RRV-T48-nsP16M was attenu-
ated in Rag1/ mice. In addition, Rag1/ mice infected with
RRV-T48-nsP16M showed a tissue-specific pattern of infection,
with RRV T48-nsP16M replicating to higher, equivalent, or lower
titers than RRV T48 in the sera, ankles, or quadriceps muscle
tissues, respectively. In both WT and Rag1/ mice, we detected
similar levels of RRV RNA in quadriceps muscle tissues at 3 dpi, a
finding consistent with our analysis of viral loads by plaque assays.
However, at both 5 and 7 dpi, RRV RNA levels in quadriceps
muscles were dramatically lower in RRV-T48-nsP16M-infected
WT and Rag1/ mice than in RRV T48-infected mice. In con-
trast, RRV RNA levels in the ankles of WT mice at 7 dpi were
equivalent (Fig. 5C and D). These data indicate that the attenuat-
ing mutations in nsP1 enhanced innate host control of RRV in
skeletal muscle tissue but had no effect on RRV RNA levels in joint
tissue.
Attenuating mutations in nsP1 enhance the sensitivity of
RRV to type I IFN. Due to the timing of the differences between
the loads of RRV T48 and RRV-T48-nsP16M in the skeletal muscle
tissues of WT and Rag1/ mice (after 3 dpi), and the correlation
of these differences with the infiltration of skeletal muscle tissue
with NK cells (15), we tested whether depletion of NK cells from
WT and Rag1/ mice or infection of mice deficient in IFN-, an
antiviral effector molecule produced by NK cells and other cell
types, would restore the loads of the nsP1 mutant virus in skeletal
muscle tissue. However, neither of these strategies recovered loads
of the nsP1 mutant virus in skeletal muscle tissue, suggesting that
some other aspect of the innate response mediates the effects ob-
served. Type I IFN is a critical regulator of alphavirus replication,
spread, and virulence (36). Numerous studies have demonstrated
that the outcome of infection with alphaviruses is more severe in
mice with defects in the type I IFN response than in WT mice
(53–62). We found that RRV T48 and RRV-T48-nsP16M were
equally virulent in 3- to 4-week-old Ifnar1/ C57BL/6 mice, sug-
gesting that type I IFN responses contribute to the attenuation of
the mutant virus RRV-T48-nsP16M in WT mice. Furthermore,
when we inoculated older Ifnar1/ mice with a low dose of virus
(5 PFU) to extend survival time, we found that the RRV-T48 and
RRV-T48-nsP16M loads in skeletal muscle tissues at 4 dpi were not
significantly different (4- to 6-fold [P, 0.05]). Our measure-
ments of type I IFN in the sera of WT mice indicated that RRV-
T48-nsP16M was not a more potent inducer of type I IFN than
RRV T48. However, in vitro type I IFN sensitivity assays demon-
strated that both RRV-T48-nsP16M and RRV-T48-nsP1 S79C;
L224I were more sensitive than RRV T48 to type I IFN. Recently,
Lidbury et al. described a mutant RRV (RRVPERS) isolated from
persistently infected murine macrophages (63). In agreement with
our findings, in which sensitivity to type I IFN in vitro correlated
with pathogenicity in vivo, RRVPERS displayed increased virulence
in mice and increased resistance to type I IFN in vitro. Five of the
12 amino acid differences between RRV T48 and RRVPERS were
located in nsP1 (63). In addition, the mutations in nsP1 that arose
during SINV passage in the presence of decreased levels of GTP
also conferred enhanced sensitivity to interferon (49, 64). Taken
together, these studies and the work reported here indicate that
sequence variation in nsP1 may influence the resistance of RRV to
the antiviral effects of type I IFN, and they suggest that modulation
of nsP1 RNA-capping activity influences IFN sensitivity. In addi-
tion, our analyses of viral loads in distinct tissues of WT and
Rag1/ mice suggest that the mutations in nsP1 enhanced the
sensitivity of RRV to type I IFN in a tissue-specific manner. These
findings raise the possibility that some aspect of the type I IFN
response that contributes to the control of RRV infection is defec-
tive in joint-associated tissues. Further investigation is needed in
order to understand the basis for the tissue- and cell type-specific
actions of type I IFN and the tissue-specific mechanisms that me-
diate the control of RRV infection.
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